Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus

被引：47

作者：

Troxell, Megan L.

Bangs, Charles D.

Lawce, Helen J.

Galperin, Ilana B.

Baiyee, Daniel

West, Robert B.

Olson, Susan B.

Cherry, Athena M.

机构：

[1] Oregon Hlth & Sci Univ, Dept Pathol, L471, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA

[3] Oregon Hlth & Sci Univ, Clin Cytogenet Lab, Portland, OR 97239 USA

[4] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2006年 / 126卷 / 05期

关键词：

Her-2/neu; erb-b2; CEP17; Smith-Magenis syndrome; retinoic acid receptor; RARA; fluorescence in situ hybridization; FISH; immunohistochemistry; breast carcinoma;

D O I：

10.1309/9EYM6VE58F2YCD9F

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional chromosome 17 probes, SMS (Smith-Magenis syndrome critical region) and RARA (retinoic acid receptor), on 7 cases with unusual Her-2/CEP17 (chromosome 17 centromere control probe) results to assess whether different measurements of chromosome 17 copy number might clarify the Her-2/neu amplicon status. Although the Her-2/CEP17 ratio scores were within normal range (< 2.0), the Her-2/SMS or Her-2/RARA ratio revealed amplification of Her-2/neu in 5 of 7 cases. Immunohistochemical analysis demonstrated Her-2/neu protein overexpression in the same 5 cases only. We describe novel application of SMS/RARA FISH probes for assessing cases with complex Her-2/CEP17 FISH patterns. Such additional data, correlated with immunohistochemical analysis, may help guide therapy in patients with breast carcinoma.

引用

页码：709 / 716

页数：8

共 33 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2] Identification and validation of an ERBB2 gene expression signature in breast cancers [J].

Bertucci, F ;

Borie, N ;

Ginestier, C ;

Groulet, A ;

Charafe-Jauffret, E ;

Adélaïde, J ;

Geneix, J ;

Bachelart, L ;

Finetti, P ;

Koki, A ;

Hermitte, F ;

Hassoun, J ;

Debono, S ;

Viens, P ;

Fert, V ;

Jacquemier, J ;

Birnbaum, D .

ONCOGENE, 2004, 23 (14) :2564-2575

[3] Current perspectives on HER2 testing:: A review of national testing guidelines [J].

Bilous, M ;

Dowsett, M ;

Hanna, W ;

Isola, J ;

Lebeau, A ;

Moreno, A ;

Penault-Llorca, F ;

Rüschoff, J ;

Tomasic, G ;

de Vijver, MV .

MODERN PATHOLOGY, 2003, 16 (02) :173-182

[4]

Bose S, 2001, Breast J, V7, P337, DOI 10.1046/j.1524-4741.2001.21018.x

[5] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[6] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast - A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study [J].

Downs-Kelly, E ;

Yoder, BJ ;

Stoler, M ;

Tubbs, RR ;

Skacel, M ;

Grogan, T ;

Roche, P ;

Hicks, DG .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1221-1227

[7] Analytical validation and interobserver reproducibility of EnzMet GenePro - A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast [J].

Downs-Kelly, E ;

Pettay, J ;

Hicks, D ;

Skacel, M ;

Yoder, B ;

Rybicki, L ;

Myles, J ;

Sreenan, J ;

Roche, P ;

Powell, R ;

Hainfeld, J ;

Grogan, T ;

Tubbs, R .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (11) :1505-1511

[8] Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].

Dowsett, M ;

Bartlett, J ;

Ellis, IO ;

Salter, J ;

Hills, M ;

Mallon, E ;

Watters, AD ;

Cooke, T ;

Paish, C ;

Wencyk, PM ;

Pinder, SE .

JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423

[9]

GLIEM T, 2005, J ASS GENET TECHNOLO, V31, P110

[10]

HOFMANN MK, 2003, P ASCO, V22, P185

← 1 2 3 4 →